Signal Transduction and Targeted Therapy

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial

By Linong Ji, Leili Gao, Ben Li, Chao Meng

Randomised trial in 250 peopleInterventions

16 weeks, double-blind, placebo-controlled, multicentre, registered NCT06569355

The paper

Linong Ji, Leili Gao, Ben Li, Chao Meng

Peking University People's Hospital; Shandong First Medical University

Signal Transduction and Targeted Therapy, 14 Aug 2026

doi.org/10.1038/s41392-026-02859-2 PubMed 42595749

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety